{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:13:30Z","timestamp":1740136410159,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Myotonic dystrophy type 1 (DM1) is the most prevalent muscular dystrophy in adults. People with DM1 might represent a high-risk population for respiratory infections, including COVID-19. Our aim was to evaluate the characteristics of COVID-19 infection and vaccination rate in DM1 patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional cohort study included 89 patients from the Serbian registry for myotonic dystrophies. Mean age at testing was 48.4 \u00b1 10.4 years with 41 (46.1%) male patients. Mean duration of the disease was 24.0 \u00b1 10.3 years.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>COVID-19 infection was reported by 36 (40.4%) DM1 patients. Around 14% of patients had a more severe form of COVID-19 requiring hospitalization. The severity of COVID-19 was in accordance with the duration of DM1. A severe form of COVID-19 was reported in 20.8% of patients who were not vaccinated against SARS-CoV-2 and in none of the vaccinated ones. The majority of 89 tested patients (66.3%) were vaccinated against SARS-CoV-2. About half of them (54.2%) received three doses and 35.6% two doses of vaccine. Mild adverse events after vaccination were recorded in 20.3% of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The percentage of DM1 patients who suffered from COVID-19 was like in general population, but with more severe forms in DM1, especially in patients with longer DM1 duration. The study indicated an overall favorable safety profile of COVID-19 vaccines among individuals with DM1 and its ability to protect them from severe COVID-19.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10072-023-06834-5","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T06:02:20Z","timestamp":1683525740000},"page":"2231-2237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myotonic dystrophy type 1 in the COVID-19 era"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7607-1313","authenticated-orcid":false,"given":"Jelena","family":"Ilic Zivojinovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-4699","authenticated-orcid":false,"given":"Katarina","family":"Djurdjevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivo","family":"Bozovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6396-717X","authenticated-orcid":false,"given":"Giovanni","family":"Meola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Peric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Azanjac Arsic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Basta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidosava","family":"Rakocevic-Stojanovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-556X","authenticated-orcid":false,"given":"Stojan","family":"Peric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"5","key":"6834_CR1","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/WCO.0000000000000128","volume":"27","author":"C Turner","year":"2014","unstructured":"Turner C, Hilton-Jones D (2014) Myotonic dystrophy: diagnosis, management and new therapies. Curr Opin Neurol 27(5):599\u2013606. https:\/\/doi.org\/10.1097\/WCO.0000000000000128","journal-title":"Curr Opin Neurol"},{"key":"6834_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12891-019-2458-7","volume":"20","author":"MP Roussel","year":"2019","unstructured":"Roussel MP, Morin M, Gagnon C et al (2019) What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review. BMC Musculoskelet Disord 20:101. https:\/\/doi.org\/10.1186\/s12891-019-2458-7","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"6834_CR3","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1212\/CON.0000000000001184","volume":"28","author":"JI Hamel","year":"2022","unstructured":"Hamel JI (2022) Myotonic dystrophy. Continuum (Minneap Minn) 28(6):1715\u20131734. https:\/\/doi.org\/10.1212\/CON.0000000000001184","journal-title":"Continuum (Minneap Minn)"},{"issue":"2","key":"6834_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ene.12237","volume":"21","author":"S Peric","year":"2014","unstructured":"Peric S, Mandic-Stojmenovic G, Markovic I, Stefanova E, Ilic V, Parojcic A, Misirlic-Dencic S, Ostojic M, Rakocevic-Stojanovic V, Kostic V (2014) Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1. Eur J Neurol 21(2):231\u2013237. https:\/\/doi.org\/10.1111\/ene.12237","journal-title":"Eur J Neurol"},{"issue":"3","key":"6834_CR5","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/ijc.32801","volume":"147","author":"R Alsaggaf","year":"2020","unstructured":"Alsaggaf R, Pfeiffer RM, Wang Y, St George DMM, Zhan M, Wagner KR, Amr S, Greene MH, Gadalla SM (2020) Diabetes, metformin and cancer risk in myotonic dystrophy type I. Int J Cancer 147(3):785\u2013792. https:\/\/doi.org\/10.1002\/ijc.32801","journal-title":"Int J Cancer"},{"issue":"2","key":"6834_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/mus.24540","volume":"52","author":"M Vujnic","year":"2015","unstructured":"Vujnic M, Peric S, Popovic S, Raseta N, Ralic V, Dobricic V, Novakovic I, Rakocevic-Stojanovic V (2015) Metabolic syndrome in patients with myotonic dystrophy type 1. Muscle Nerve 52(2):273\u2013277. https:\/\/doi.org\/10.1002\/mus.24540","journal-title":"Muscle Nerve"},{"issue":"5","key":"6834_CR7","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.3390\/ijms23052901","volume":"23","author":"M Garc\u00eda-Puga","year":"2022","unstructured":"Garc\u00eda-Puga M, Saenz-Anto\u00f1anzas A, Matheu A, L\u00f3pez de Munain A (2022) Targeting myotonic dystrophy type 1 with metformin. Int J Mol Sci 23(5):2901. https:\/\/doi.org\/10.3390\/ijms23052901","journal-title":"Int J Mol Sci"},{"key":"6834_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2020.08.011","volume":"551","author":"E Seyed Hosseini","year":"2020","unstructured":"Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H (2020) The novel coronavirus disease-2019 (COVID-19): mechanism of action, detection and recent therapeutic strategies. Virology 551:1\u20139. https:\/\/doi.org\/10.1016\/j.virol.2020.08.011","journal-title":"Virology"},{"issue":"6","key":"6834_CR9","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s13760-020-01514-z","volume":"121","author":"S Dhont","year":"2021","unstructured":"Dhont S, Callens R, Stevens D, Bauters F, De Bleecker JL, Derom E, Van Braeckel E (2021) Myotonic dystrophy type 1 as a major risk factor for severe COVID-19? Acta Neurol Belg 121(6):1761\u20131765. https:\/\/doi.org\/10.1007\/s13760-020-01514-z","journal-title":"Acta Neurol Belg"},{"issue":"2","key":"6834_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/mus.27761","volume":"67","author":"T Saito","year":"2023","unstructured":"Saito T, Saito T, Hashimoto H, Ogata K, Kobayashi M, Takada H, Kuru S, Kimura T, Nakamura A, Matsumura T (2023) Safety and immunogenicity of mRNA COVID-19 vaccine in inpatients with muscular dystrophy. Muscle Nerve 67(2):117\u2013123. https:\/\/doi.org\/10.1002\/mus.27761","journal-title":"Muscle Nerve"},{"issue":"372","key":"6834_CR11","doi-asserted-by":"publisher","first-page":"n136","DOI":"10.1136\/bmj.n136","volume":"22","author":"W Shah","year":"2021","unstructured":"Shah W, Hillman T, Playford ED, Hishmeh L (2021) Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ 22(372):n136. https:\/\/doi.org\/10.1136\/bmj.n136","journal-title":"BMJ"},{"issue":"5","key":"6834_CR12","doi-asserted-by":"publisher","first-page":"e2111417","DOI":"10.1001\/jamanetworkopen.2021.11417","volume":"4","author":"T Nasserie","year":"2021","unstructured":"Nasserie T, Hittle M, Goodman SN (2021) Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open 4(5):e2111417. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.11417","journal-title":"JAMA Netw Open"},{"issue":"2","key":"6834_CR13","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/all.14657","volume":"76","author":"YD Gao","year":"2021","unstructured":"Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Br\u00fcggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA (2021) Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76(2):428\u2013455. https:\/\/doi.org\/10.1111\/all.14657","journal-title":"Allergy"},{"key":"6834_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13760-022-02121-w","volume":"24","author":"S Peric","year":"2022","unstructured":"Peric S, Rankovic M, Bozovic I, Radosavljevic V, Marjanovic I, Basta I, Lavrnic D (2022) COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis. Acta Neurol Belg 24:1\u20138. https:\/\/doi.org\/10.1007\/s13760-022-02121-w","journal-title":"Acta Neurol Belg"},{"issue":"4","key":"6834_CR15","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3233\/JND-220794","volume":"9","author":"L Lewis","year":"2022","unstructured":"Lewis L, Eichinger K, Dilek N, Higgs K, Walker M, Palmer D, Cooley JM, Johnson N, Tawil R, Statland J (2022) Understanding the perseverance of the muscular dystrophy community one-year into the COVID-19 pandemic. J Neuromuscul Dis 9(4):517\u2013523. https:\/\/doi.org\/10.3233\/JND-220794","journal-title":"J Neuromuscul Dis"},{"key":"6834_CR16","unstructured":"Bird TD. Myotonic dystrophy type 1. 1999 Sep 17 [Updated 2021 Mar 25]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2023. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1165\/"},{"key":"6834_CR17","unstructured":"WHO. Serbia: WHO Coronavirus Disease (COVID-19) dash-board with vaccination data. Available from: https:\/\/covid19. who.int\/region\/euro\/country\/rs (Accessed February 2023)"},{"key":"6834_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/22221751.2022.2155250","volume":"12","author":"K Miyashita","year":"2023","unstructured":"Miyashita K, Hozumi H, Furuhashi K, Nakatani E, Inoue Y, Yasui H, Karayama M, Suzuki Y, Fujisawa T, Enomoto N, Inui N, Ojima T, Suda T (2023) Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study. Emerg Microbes Infect 12:1. https:\/\/doi.org\/10.1080\/22221751.2022.2155250","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"6834_CR19","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3855\/jidc.15653","volume":"17","author":"M Mazzitelli","year":"2023","unstructured":"Mazzitelli M, Trevenzoli M, Brundu M, Squarzoni G, Cattelan AM (2023) COVID-19 and myotonic dystrophy: case reports and systematic review. J Infect Dev Ctries 17(2):182\u2013187. https:\/\/doi.org\/10.3855\/jidc.15653","journal-title":"J Infect Dev Ctries"},{"issue":"3","key":"6834_CR20","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/mus.27349","volume":"64","author":"K Eichinger","year":"2021","unstructured":"Eichinger K, Lewis L, Dilek N, Higgs K, Walker M, Palmer D, Cooley JM, Johnson N, Tawil R, Statland J (2021) A patient-focused survey to assess the effects of the COVID-19 pandemic and social guidelines on people with muscular dystrophy. Muscle Nerve 64(3):321\u2013327. https:\/\/doi.org\/10.1002\/mus.27349","journal-title":"Muscle Nerve"},{"key":"6834_CR21","unstructured":"Our World in data. Coronavirus (COVID-19) vaccinations. Available from: https:\/\/ourworldindata.org\/covid-vaccinations (Accessed February 2023)"},{"issue":"3","key":"6834_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10072-016-2778-4","volume":"38","author":"S Peric","year":"2017","unstructured":"Peric S, Rakocevic Stojanovic V, Mandic Stojmenovic G, Ilic V, Kovacevic M, Parojcic A, Pesovic J, Mijajlovic M, Savic-Pavicevic D, Meola G (2017) Clusters of cognitive impairment among different phenotypes of myotonic dystrophy type 1 and type 2. Neurol Sci 38(3):415\u2013423. https:\/\/doi.org\/10.1007\/s10072-016-2778-4","journal-title":"Neurol Sci"},{"issue":"4","key":"6834_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/ane.12173","volume":"129","author":"S Peric","year":"2014","unstructured":"Peric S, Sreckov M, Basta I, Lavrnic D, Vujnic M, Marjanovic I, Rakocevic Stojanovic V (2014) Dependent and paranoid personality patterns in myotonic dystrophy type 1. Acta Neurol Scand 129(4):219\u2013225. https:\/\/doi.org\/10.1111\/ane.12173","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"6834_CR24","doi-asserted-by":"publisher","first-page":"e42261","DOI":"10.2196\/42261","volume":"24","author":"A Ljaji\u0107","year":"2022","unstructured":"Ljaji\u0107 A, Prodanovi\u0107 N, Medvecki D, Ba\u0161aragin B, Mitrovi\u0107 J (2022) Uncovering the reasons behind COVID-19 vaccine hesitancy in Serbia: sentiment-based topic modeling. J Med Internet Res 24(11):e42261. https:\/\/doi.org\/10.2196\/42261","journal-title":"J Med Internet Res"},{"key":"6834_CR25","doi-asserted-by":"publisher","first-page":"1056670","DOI":"10.3389\/fpubh.2022.1056670","volume":"10","author":"L Markovic-Denic","year":"2022","unstructured":"Markovic-Denic L, Popadic D, Jovanovic T et al (2022) Developing COVID-19 vaccine recommendations during the pandemic: the experience of Serbia\u2019s Expert Committee on Immunization. Front Public Health 10:1056670. https:\/\/doi.org\/10.3389\/fpubh.2022.1056670","journal-title":"Front Public Health"},{"key":"6834_CR26","doi-asserted-by":"publisher","first-page":"6408","DOI":"10.26355\/eurrev_202110_27014","volume":"25","author":"D \u017divanovi\u0107","year":"2021","unstructured":"\u017divanovi\u0107 D, Jovin VM, Javorac J, Ili\u0107 M, Zeli\u0107 P (2021) Commentary: registered adverse events following COVID-19 immunization in Serbia. European Review for Medical and Pharmacological Sciences 25:6408\u20136410. https:\/\/doi.org\/10.26355\/eurrev_202110_27014","journal-title":"European Review for Medical and Pharmacological Sciences"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06834-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06834-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06834-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T04:07:21Z","timestamp":1686370041000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06834-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["6834"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06834-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"type":"print","value":"1590-1874"},{"type":"electronic","value":"1590-3478"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"19 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Ethical Board of the Neurology Clinic, University Clinical Center of Serbia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Each author has read and approved the final manuscript version for submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}